Blog: Research

The team are recruiting 200 people with advanced progressive MS

12 August 2021

Source MS Society: Last year, we announced a new trial testing if a drug called cladribine can slow down the worsening of arm and hand movement for people with advanced primary or secondary progressive MS.

Machine learning identifies new subtypes of MS from MRI scans

14 May 2021

Source MS Trust: Researchers wanted to find out if there are hidden patterns in MRI brain scans taken over time that would better identify biological differences in MS activity and detect progression earlier.

Introducing Octopus – the world’s first multi-arm, multi-stage trial for MS

5 May 2021

Source MS Society: We’re pleased to introduce Octopus - our revolutionary, multi-arm, multi-stage trial that will transform the way we test treatments for progressive MS.

Ofatumumab licensed for active relapsing-remitting MS in UK

9 April 2021

Source MS Society: The Medicines and Healthcare products Regulatory Agency (MHRA), and European Commission (EC) have licenced ofatumumab to treat adults with active relapsing MS.

UK to test existing drugs as treatment for MS in world-first trial

24 March 2021

Source The Guardian: Researchers will test several drugs at once to speed up identification of those that slow or reverse symptoms

Why do our brains stop repairing myelin as we get older?

11 March 2021

Source MS Society: A new study has discovered a specific gene plays a major role in myelin repair becoming less effective as we age.

To stop MS from getting worse, we need to find ways to repair damaged myelin – the protective coating around nerves in our brains.

Although our bodies have the natural ability to repair myelin, this process breaks down in MS. Recently, researchers have discovered that ageing is a key cause of this breakdown. But they aren’t sure exactly why....

Mindfulness-based interventions for mental well-being among people with MS

5 March 2021

An interesting study on mindfulness-based interventions for mental well-being among people with multiple sclerosis.